Mathematical Disease Progression Modeling in Type 2/3 Spinal Muscular Atrophy

Muscle Nerve. 2018 Oct;58(4):528-535. doi: 10.1002/mus.26178. Epub 2018 Aug 28.

Abstract

Introduction: We propose a mathematical model to empirically describe spinal muscular atrophy (SMA) progression assessed by the 3 domains of the motor function measure (MFM) scale. The model implements development and deterioration of muscle function.

Methods: Nonlinear mixed-effects modeling was applied to data from 2 observational studies and 1 prospective clinical efficacy study comprising 190 healthy participants and 277 patients with type 2/3 SMA.

Results: The model evidenced correlations between parameter estimates for different MFM domains. Slower development in MFM domain D1 (standing and transfers) was associated with faster deterioration for MFM domains D2 (proximal and axial motricity) and D3 (distal motor function).

Discussion: The model describes all individual data well, although sparseness and variability of observational data prevented numerically stable estimation of parameters. Treatment duration in clinical studies was too limited to determine a proper drug-effect model that could differentiate between symptomatic and disease modifying effects. Muscle Nerve 58: 528-535, 2018.

Keywords: disease progression; drug development; mathematical modeling; motor function measure; spinal muscular atrophy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Cholestenones / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Disease Progression
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Models, Theoretical
  • Nonlinear Dynamics
  • Observational Studies as Topic
  • Spinal Muscular Atrophies of Childhood / drug therapy
  • Spinal Muscular Atrophies of Childhood / physiopathology*
  • Young Adult

Substances

  • Cholestenones
  • olesoxime